The United States Food and Drug Administration (FDA) has taken note of the burgeoning interest in the potential use of psychedelic pharmaceuticals for the treatment of mental health disorders. In June, the FDA released its inaugural draft guidance aimed at developers of these psychedelic substances for medical use. This guidance zeroes in on what are traditionally categorized as “classic psychedelics,” namely psilocybin and LSD, which are known as “5-HT2 agonists,” as well as entactogens. The agency’s progress demonstrates a clear departure from its approach to cannabis, reflecting significant differences in federal attitudes towards these two categories of substances. More details can be found on JD Supra.
Despite increasing legislation at the state level to decriminalize or legalize cannabis for both medicinal and recreational use, the Federal outlook remains unchanged. The FDA continues to classify cannabis as a Schedule I substance under the Controlled Substances Act (CSA), which deems it as having a high potential for abuse, no currently accepted medical use, and a lack of accepted safety under medical supervision. Indeed, the FDA has explicitly stated that it does not have the power to change the legal status of cannabis, asserting that this falls under the jurisdiction of the DEA and Congress.
Conversely, certain psychedelics maintain a less restrictive legal status at the federal level. Psilocybin, for instance, though also classified as a Schedule I substance, has been granted Breakthrough Therapy Designation by the FDA for the treatment of major depressive disorder. This status allows the FDA to expedite the development and review process for a medicinal drug, reflecting an implicit acknowledgement of its potential therapeutic value.
Such contrasting views of cannabis and psychedelics by federal agencies indicate that the legal landscape for these substances is far from homogeneous, complicating the approach for corporations focusing on drug development or investment in this new and rapidly evolving area. Legal professionals must therefore navigate this multifaceted landscape with a keen understanding of these nuances in federal policy, which can offer clues to future regulatory shifts or legal challenges.